Quantcast

Latest gout Stories

2011-04-12 08:15:00

WASHINGTON, April 12, 2011 /PRNewswire/ -- Tart cherries have a unique combination of powerful antioxidants that may help reduce risk factors for heart disease, according to new research presented at the Experimental Biology annual meeting in Washington, DC. In a series of three studies, researchers from University of Michigan, University of Arizona and Brunswick labs studied the antioxidant levels and anti-inflammatory benefits of tart cherries. They found: Reduced Inflammation and...

2011-04-06 09:15:00

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Getting the word out about preventing and treating gouty arthritis has new urgency with the number of Americans suffering from this form of arthritis now topping the 8 million mark. If left untreated, gout can be disabling. Gout is also associated with other serious health conditions, making it a complex diagnosis and treatment challenge for physicians. In addition to the core patient demographic of men age 40 plus, post-menopausal women are at...

2011-03-11 07:30:00

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and announced fourth quarter and full-year 2010 financial results. "With approximately $160 million in cash as of the end of February, we are in an excellent financial position," commented Barry D. Quart, PharmD, Ardea's president and chief executive...

2011-02-28 06:30:00

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period. Patients who received ARCALYST at a weekly, self-administered, subcutaneous dose of either 160 milligrams (mg) or 80...

2011-02-17 06:00:00

TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones. "2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein...

2011-02-11 00:00:45

Gout was known was a man's disease until a recent medical study told another story. What's happening to alter the pain condition equation? Medical science, leading edge technology and natural pain relief ingredients have found common ground in treating localized pain conditions. A new brand, MyOmega 3 plus, (http://www.goutpain.ultimizer.com), provides efficient targeted relief of inflammation and pain for 6 plus hours per application. Chicago, IL (PRWEB) February 10, 2011 In 2010,...

2011-01-27 00:02:59

A new topical formula for treatment of pain flares and chronic pain conditions is now available direct from the manufacturer. Concept Laboratories combines the best in natural pain relief ingredients with a nanotechnology breakthrough that provides cooling comfort for fibromyalgia, arthritis and even intense gout flares (http://www.goutpain.ultimizer.com). The new brand, MyOmega 3, is a deep penetrating topical pain spray and cream that relieves targeted inflammation and pain for 6 + hours...

2011-01-18 15:27:56

The amount of uric acid in one's joints may increase the likelihood of severe osteoarthritis, the most common form of arthritis worldwide, according to researchers at Duke University Medical Center. Osteoarthritis is a debilitating joint degeneration for which no drug has been proven to slow or halt its progression. Physicians can only offer to treat the symptoms associated with osteoarthritis, and people with the condition are often subject to a reduced quality of life. "Finding a way to...

2011-01-10 07:00:00

SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has earned a $15 million milestone payment from Bayer HealthCare AG (Bayer) under the terms of their April 2009 global license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications. This milestone was triggered by the initiation of a Phase 2 clinical study evaluating BAY 86-9766 in combination with...

2011-01-06 15:00:00

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol. Allopurinol currently accounts for greater than 90% of the unit sales of chronic gout prescription medications; however, in controlled trials, only 30-40% of gout patients respond adequately to allopurinol as defined by the...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related